One-Shot gene therapy could replace monthly eye injections for wet AMD

NCT ID NCT06550011

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage trial tests a single injection of ABI-110 gene therapy into the eye for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it is safe and can reduce the need for frequent anti-VEGF injections by helping the eye produce its own medicine. About 18 adults aged 50 to 89 with wet AMD will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AMD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bay Area Retina Associates

    Walnut Creek, California, 94598, United States

  • California Retina Consultants

    Bakersfield, California, 93309, United States

  • Retina Consultants of Texas

    The Woodlands, Texas, 77384, United States

  • Retina Consultants of Texas - San Antonio

    San Antonio, Texas, 78240, United States